Physician profile
Robert Flowers
NPI 1437188067
$4,849.53
in general payments reported to CMS, 2019-2025
30 companies · $880 in 2025
The $880 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $315 · 2021: $663 · 2022: $994 · 2023: $664 · 2024: $700 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,386.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $566.74 | 2019-2025 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.60 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.22 | 2019-2023 | |
| Novo Nordisk INC | $213.88 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $196.07 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $180.43 | 2019-2024 | |
| Amgen INC. | $176.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $156.75 | 2019-2022 | |
| Lundbeck LLC | $151.81 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $133.17 | 2019-2021 | |
| Pfizer INC. | $132.06 | 2019-2023 | |
| Horizon Therapeutics Plc | $131.17 | 2020-2022 | |
| Lilly USA, LLC | $103.69 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.88 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $82.52 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $50.30 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $50.08 | 2023-2024 | Myrbetriq, Veozah |
| Sanofi-Aventis U.S. LLC | $44.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $41.84 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $33.81 | 2024-2025 | Rexulti, Nuedexta |
| Daiichi Sankyo INC. | $20.19 | 2025 | Injectafer |
| Sunovion Pharmaceuticals INC. | $19.13 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.16 | 2021 | |
| Allergan, INC. | $16.01 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $14.57 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.79 | 2025 | Caplyta |
| Radius Health, INC. | $13.61 | 2020 | |
| Mylan Specialty L.P. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.